AstraZeneca and FibroGen’s roxadustat, not yet filed in U.S., nabs 2nd anemia nod in China

22nd August 2019 Uncategorised 0

FibroGen has not even filed its AstraZeneca-partnered oral anemia drug roxadustat for U.S. regulatory approval. But now, with a second nod in China, the blockbuster hopeful is allowed to treat all chronic kidney disease patients with anemia, regardless of whether they require dialysis.

More: AstraZeneca and FibroGen’s roxadustat, not yet filed in U.S., nabs 2nd anemia nod in China
Source: fierce